Efficacy and Safety of Ecabet Sodium as an Adjuvant Therapy for <i>Helicobacter pylori</i> Eradication: A Systematic Review and Meta‐Analysis

Wang, Youhua; Wang, Ben; Lv, Zhi Fa; Yang, Yang; Wang, Fucai; Wang, Hui; Chen, Shuping; Xie, Yong; Zhou, Xiaojiang

doi:10.1111/hel.12136

Cited by 10 publications

(6 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A similar agent to bismuth, ecabet sodium, can also be used as a component of a four-drug regimen against H. pylori. A meta-analysis comparing regimens containing ecabet to triple therapies showed that the eradication rate in the ecabet-containing quadruple therapy group was higher than that in the standard triple therapy group (85 vs 75%, OR 1.757 95%CI: 1.307-2.362) [50].…”

Section: Bismuth Therapymentioning

confidence: 99%

Treatment of Helicobacter pylori Infection 2015

et al. 2015

View full text Add to dashboard Cite

Many interesting articles have been published from many parts of the world over the last year assessing different issues around Helicobacter pylori eradication therapy. This article will address the published literature over the last year pertaining to the topic of treatment of H. pylori infection. The main themes that emerge are assessing the efficacy of standard triple therapy, as well as exploring new first-line treatments, mainly optimized nonbismuthand bismuth-containing quadruple therapies with some promising data also emerging on dual therapy. There was also considerable progress in investigating antibiotic resistance rates with much more data emerging from varied parts of the world compared to recent years. There have also been advances in the use of adjunctive therapies, especially probiotic therapies. Undoubtedly, the eradication of H. pylori remains a worthwhile goal to alleviate the burden of diseases caused by the complications of this infection, including dyspepsia, peptic ulcer disease, and gastric cancer. Triple TherapyA number of studies have been published this year, primarily from Asia, on standard triple therapy which remains the regimen recommended in the majority of published guidelines. A meta-analysis from China showed suboptimal eradication rates in this part of the world with a pooled rate of 74.5% which was inferior when compared to sequential therapy with relative risk (RR) = 0.863 [1]. Better, but still insufficient, eradication rates however were noted in Korea, with an overall eradication rate of 84% from 2005 to 2010 [2]. In Japan, while rates remain clearly suboptimal, eradication rates by per-protocol (PP) analysis have not changed between 2001 and 2010 although there has been a decline in eradication rates by intention-to-treat (ITT) analysis [3]. Another Japanese group from a region of higher clarithromycin resistance compared 7-day standard triple therapy with rabeprazole, amoxicillin, and clarithromycin (RAC) to rabeprazole, amoxicillin, and metronidazole (RAM). They found ITT eradication rates of 73% in the RAC group and 91% in the RAM group [4]. In other regions, a study in Nigeria found an eradication rate of 87% for triple therapy with no difference between 7 and 10 days of treatment [5]. An interesting study from Spain showed that when clarithromycin susceptibility testing is carried out prior to treatment, eradication rates reach 94% compared to 72% for empiric treatment, based on a 10-day regimen [6]. Similar findings emerged from a Japanese study where 97% eradication was achieved when antimicrobial susceptibility testing was carried out prior to treatment, and it was 95% eradication in a Korean study [7,8]. Another study from Spain examined the optimal first-line eradication regimen for patients with penicillin allergy and reported ITT eradication rates with omeprazole-clarithromycin-metronidazole of only 57% compared to 74% for PPI-bismuth-tetracyclinemetronidazole, with equivalent rates of compliance and adverse events. In this specific group for second-line treat...

show abstract

Section: Bismuth Therapymentioning

confidence: 99%

Treatment of Helicobacter pylori Infection 2015

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The results showed that there was no statistically significant difference in the incidence of adverse events between the minocycline group and the tetracycline group, with both showing relatively high rates (55.4% [102/184] and 53.3% [98/184], P > 0.05). But a meta‐analysis of randomized controlled trials on minocycline quadruple therapy for eradicating H. pylori 17 showed that the incidence of adverse reactions in the minocycline quadruple therapy group was similar to that in comparator groups using doxycycline, tetracycline, clarithromycin, and others. The results of our study showed that the common adverse reactions associated with the minocycline‐vonoprazan regimen were abdominal discomfort and nausea.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of bismuth quadruple regimens containing minocycline and vonoprazan for eradication of Helicobacter pylori: Real‐world evidence

He,

Ou,

Zhu

et al. 2024

JGH Open

View full text Add to dashboard Cite

Background and AimTo evaluate the efficacy and safety of minocycline, vonoprazan, amoxicillin, and bismuth quadruple therapy for Helicobacter pylori (H. pylori) treatment.MethodsFrom August 2022 to May 2023, clinical data were collected from patients who received H. pylori eradication treatment at West China Fourth Hospital, Sichuan University. One group received the MVAB regimen (amoxicillin, minocycline, vonoprazan, and colloidal bismuth pectin), while another group received the FOAB regimen (amoxicillin, furazolidone, omeprazole, and colloidal bismuth pectin), both administered for 14 days. Follow‐up assessments of safety and compliance were conducted within 1 week after treatment completion. One and a half months after treatment, the success of eradication was evaluated using the urea breath test.ResultsFor the MVAB regimen as a first‐line treatment, the eradication rate was 90.1% (127/141, 95% CI: 85.1–95.1%) in the ITT analysis and 93.4% (127/136, 95% CI: 89.2–97.6%) in the PP analysis as a first‐line treatment. As a second‐line treatment, the eradication rate was 91.3% (21/23, 95% CI: 78.8–103.8%) in both analyses. For the FOAB regimen as a first‐line treatment, the eradication rate was 98.0% (50/51, 95% CI: 94.1–101.2%) in the ITT analysis and 100% (50/50, 95% CI: 100%) in the PP analysis. As a second‐line treatment, the eradication rate was 100% (6/6, 95% CI: 100%) in both analyses. Moreover, there was no significant difference in the incidence of adverse events between the two groups (MVAB regimen: 5.5% and FOAB regimen: 8.8%; P > 0.05).ConclusionsThe MVAB regimen could indeed be a viable alternative treatment option to conventional therapies.

show abstract

“…As well, the resistance in bacteria promotes us to find new taps of drugs, and the natural kingdom seems to be an untapped source for promising antibacterial agents [1][2][3]. In addition, green synthesis of metallic nanoparticles has been adopted to accommodate various bio-materials (e.g., bacteria, fungi, algae, and plant extracts) [4] as a simple and easy process [5] used as antimicrobial agents [6], and possessed antifungal, anti-bacterial, anti…”

Section: Introductionmentioning

confidence: 99%

Green Synthesis of Silver NPs based on Arenga engleri leaves extract: Characterization and in-vitro Helicobacter pylori activity

et al. 2022

View full text Add to dashboard Cite

Globally, the infection with Helicobacter pylori is considered the most prevalent issue that causes chronic inflammation of t stomach. In this study, the phytochemical investigation of Arengaengleri (family Arecaceae) leaves extract that used to prepare the AgNPs was performed and examined for their potential activity against H. pylori. The phytochemical results revealed the presence of different phenolic contents dep content and total flavonoid content measurements, and HPLC profiling. Besides, the percent of unsaturated and saturated fatty acids were 51.39 % and 31.47 %, respectively. The as spectroscopy, TEM, XRD, and Zeta potential. The synthesized AgNPs displayed promising anti H. pylori with MIC = 7.81 µg/mL, while the A. engleri extract showed weak activity with MIC = 500 µg/mL compa µg/mL after 3 days ofincubation. In conclusion, the organic acids, phenolic, and flavonoid contents of A. engleri extract wer used as capping agents to prepare simple, low their high penetration towards the bacterial cell of H. pylori and destroyed it.

show abstract

Efficacy and Safety of Ecabet Sodium as an Adjuvant Therapy for Helicobacter pylori Eradication: A Systematic Review and Meta‐Analysis

Abstract: Supplementation with ecabet sodium during H. pylori eradication therapy improves the eradication rate. The use of ecabet sodium does not increase the side effects based on our meta-analysis.

Cited by 10 publications

References 35 publications

Treatment of Helicobacter pylori Infection 2015

Treatment of Helicobacter pylori Infection 2015

Efficacy and safety of bismuth quadruple regimens containing minocycline and vonoprazan for eradication of Helicobacter pylori: Real‐world evidence

Green Synthesis of Silver NPs based on Arenga engleri leaves extract: Characterization and in-vitro Helicobacter pylori activity

Contact Info

Product

Resources

About